Mechanisms of normal and tumor-derived angiogenesis

American Journal of Physiology - Cell Physiology

Volumn 282, Issue 5 51-5, 2002, Pages

  Papetti, Michael ^a   Herman, Ira M ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Blood vessel; Cancer; Endothelium; Growth; Pericyte

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENIN; ANGIOTROPHIN; BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR 5; CADHERIN; EPHRIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GELATINASE A; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN LYASE; INTEGRIN; INTERLEUKIN 8; NICOTINAMIDE; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN; THROMBOPLASTIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; CANCER; CELL PROLIFERATION; DIFFUSION; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TISSUE METABOLISM; TUMOR VASCULARIZATION;

EID: 0036088478     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00389.2001     Document Type: Review

References (266)

1. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect
2. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
3. Growth regulation of the vascular system: Evidence for a metabolic hypothesis
4. Long-term electrical stimulation of rabbit skeletal muscle increases growth of paired arteries and veins
5. Inhibition of tumor growth correlates with the expression level of a human angiostatin transgene in transfected B16F10 melanoma cells
6. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes
7. Signal transduction and signal modulation by cell adhesion receptors: The role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins
8. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
9. v integrins
10. The effects of platelet-derived growth factor in cultured microvessel endothelial cells
11. Role of interleukin-8 in tumor growth and metastasis of human melanoma
12. The interferons: A biological system with therapeutic potential in viral infections
13. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF β-receptors
14. Vascular development: Cellular and molecular regulation
15. Functional interaction of β-catenin with the transcription factor LEF-1
16. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia
17. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
18. Cachectin and tumour necrosis factor as two sides of the same biological coin
19. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance
20. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
21. 3 for angiogenesis
22. Disruption of angiogenesis by PEX, a non-catalytic metalloproteinase fragment with integrin binding activity
23. 3
24. Inhibition of cell motility by interferon
25. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate
26. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR
27. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells
28. Vascular endothelial growth factor C induces angiogenesis in vivo
29. Angiogenesis in cancer and other diseases
30. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis
31. Role of tissue factor in embryonic blood vessel development
32. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
33. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin)
34. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
35. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor
36. 3 on vascular cells during wound repair
37. The human hematopoietic colony-stimulating factors
38. Fibroblast growth factors are required for efficient tumor angiogenesis
39. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line
40. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
41. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V
42. Growth factor effects on cells of the vascular wall: A survey
43. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
44. Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro
45. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloing
46. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
47. Endothelial cell proliferation as a novel approach to targeting tumour therapy
48. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression
49. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells
50. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice
51. Phosphorylation of the endothelial nitric oxide synthase at Ser-1177 is required for VEGF-induced endothelial cell migration
52. Purification and characterization of a naturally occurring vascular endothelial growth factor placenta growth factor heterodimer
53. 1-Butyryl-glycerol: A novel angiogenesis factor secreted by differentiating adipocytes
54. 3 prevents maturation of blood vessels during embryonic neovascularization
55. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo
56. Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors
57. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
58. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
59. PDGF mediates cardiac microvascular communication
60. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2
61. v integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
62. 3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis
63. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells
64. Restricted expression pattern of vegf-d in the adult and fetal mouse: High expression in the embryonic lung
65. Progress in antiangiogenic gene therapy of cancer
66. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1
67. Molecular and biological properties of vascular endothelial growth factor
68. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
69. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
70. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells
71. The ephrins and Eph receptors in neural development
72. Angiogenesis in cancer, vascular, rheumatoid, and other disease
73. What is the evidence that tumors are angiogenesis dependent?
74. Angiogenic factors
75. A heparin-binding angiogenic protein-basic fibroblast growth factor - is stored within basement membrane
76. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone
77. Isolation of a tumor factor responsible or angiogenesis
78. Role of the Flt-1 receptor kinase in regulating the assembly of the vascular endothelium
79. Induction of human vascular endothelial stress fibres by fluid shear stress
80. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo
81. v integrins
82. Inhibition of endothelial cell proliferation by gamma-interferon
83. Tumor induction of VEGF promoter activity in stromal cells
84. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis
85. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin
86. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidyl-inositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
87. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development
88. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
89. Isolation and characterization of a vascular cell mitogen produced by pituitary-derived folliculo stellate cells
90. Structural characterization and biological functions of fibroblast growth factor
91. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
92. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
93. Cell adhesion: The molecular basis of tissue architecture and morphogenesis
94. Neuropilin is a receptor for the axonal chemorepellant semaphorin III
95. Density-dependent accumulation of basic fibroblast growth factor in the subendothelial matrix
96. Mechanism of action and in vivo role of platelet-derived growth factor
97. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse
98. The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells
99. Response of microvascular endothelial cells to biological response modifiers
100. Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model
101. Purified monocyte-derived angiogenic substance (angiotropin) induces controlled angiogenesis associated with regulated tissue proliferation in rabbit skin
102. Purified monocyte-derived angiogenic substance (angiotropin) stimulates migration, phenotypic changes, and "tube formation" but not proliferation of capillary endothelial cells in vitro
103. β3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival
104. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
105. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
106. Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands
107. Dual regulation of vascular endothelial growth factor availability by genetic and proteolytic mechanisms
108. Vascularization of the human fetal retina: Roles of vasculogenesis and angiogenesis
109. 1-adrenergic blocker treatment
110. Differential expression of thrombospondin 1, 2, and 3 during murine development
111. Expression of vascular endothelial growth factor receptors in smooth muscle cells
112. Transport of molecules in the tumor interstitium: A review
113. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues
114. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
115. A requirement for neuropilin-1 in embryonic vessel formation
116. Vascular permeability factor, an endothelial cell mitogen related to PDGF
117. Vascular permeability factor/vascular endothelial growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins
118. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
119. 1 with the central cell-binding domain of fibronectin
120. Identification of hypoxia-inducible factor-1 (HIF-1) ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide
121. Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice
122. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs
123. Regulators of angiogenesis
124. Molecular angiogenesis
125. Angiopoietin-1 induces sprouting angiogenesis in vitro
126. Interleukin-8 as a macrophage-derived mediator of angiogenesis
127. Stimulation of neovascularization by human rheumatoid synovial tissue macrophages
128. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels
129. Neuropilin is a semaphorin III receptor
130. The mouse tie receptor tyrosine kinase gene: Expression during embryonic angiogenesis
131. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
132. Chemical identification of a tumor-derived angiogenic factor
133. A novel endothelial-specific membrane protein is a marker of cell-cell contacts
134. Conversion of a high molecular weight latent β-TGF from chicken embryo fibroblasts into a low molecular weight active β-TGF under acidic conditions
135. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms
136. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4
137. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α
138. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities
139. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
140. Induction of angiogenesis by bovine brain derived class 1 heparin-binding growth factor
141. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis
142. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium
143. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus
144. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor
145. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14
146. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides
147. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
148. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1
149. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor
150. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro
151. The transforming growth factor-β family
152. Vascular cells respond differentially to transforming growth factors beta 1 and beta 2 in vitro
153. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases
154. Neuropilin is a placenta growth factor-2 receptor
155. In vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor-induced proteinases
156. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
157. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
158. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
159. Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice
160. Basic fibroblast growth factor induces angiogenesis in vitro
161. The regulation of neovascularization of matrix metalloproteinases and their inhibitors
162. Inhibitory action of transforming growth factor beta on endothelial cells
163. Bifunctional effects of transforming growth factor-β (TGF-β) on endothelial cell growth correlate with phenotypes of TGF-β binding sites
164. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro
165. The interleukin network and lymphoid development
166. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
167. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
168. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovaseularization
169. Vascular endothelial growth factor B, a novel growth factor for endothelial cells
170. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform
171. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family
172. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells
173. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis
174. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines
175. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-α-induced angiogenesis
176. Placenta growth factor potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
177. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains
178. Putative tyrosine kinases expressed in K-562 human leukemia cells
179. Interleukin-4: A prototypic immunoregulatory lymphokine
180. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro
181. Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity
182. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
183. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity
184. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth
185. Inhibition by methylprednisolone acetate suggests an indirect mechanism for TGF-B induced angiogenesis
186. Specificity, diversity, and regulation in TGF-β superfamily signaling
187. Platelet-derived growth factor (BB homodimer), transforming growth factor-β1, and basic fibroblast growth factor in dermal wound healing neovessel and matrix formation and cessation of repair
188. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta
189. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells
190. Interleukin-4 and cancer therapy
191. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium
192. Circulating endothelial precursors: Mystery, reality, and promise
193. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene
194. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis
195. Gelatinase A activity directly modulates melanoma cell adhesion and spreading
196. Hemodynamic forces are complex regulators of endothelial gene expression
197. Utero-ovarian interactions during early pregnancy: Role of conceptus-induced vasodilation
198. Expression of the angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in the ovary
199. Human recombinant interferon α-2a inhibits angiogenesis of chick area vasculosa in shell-less culture
200. Differentiation of endothelium
201. Mechanisms of angiogenesis
202. Transforming growth factors: Isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction
203. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
204. The splice variants of vascular endothelial growth factor (VEGF) and their receptors
205. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
206. Extrajunctional distribution of N-cadherin in cultured human endothelial cells
207. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
208. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture
209. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans
210. Transforming growth factor-α: A more potent angiogenic mediator than epidermal growth factor
211. 1 integrins
212. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
213. 3 integrin, osteopontin, and thrombin
214. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines
215. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice
216. Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor
217. Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor
218. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-induced angiogenesis
219. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas
220. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
221. Angiogenin supports endothelial and fibroblast cell adhesion
222. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice
223. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia
224. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis
225. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis
226. 3 during angiogenesis
227. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
228. Increased vascularization in mice overexpressing angiopoietin-1
229. Expression and modulation of the vitronectin receptor on human dermal microvascular endothelial cells
230. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
231. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA
232. Protamine is an inhibitor of angiogenesis
233. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4
234. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
235. Human endothelial cells are chemotactic to endothelial cell growth factor and heparin
236. Regulation of cellular functions by extracellular matrix
237. Fibroblast growth factors
238. The histological structure of some human lung cancers and the possible implications for radiotherapy
239. Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice
240. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
241. Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family
242. Cellular and viral ligands that interact with the EGF receptor
243. Quantitative analysis of vascular endothelial growth factor in primary breast cancer
244. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies
245. Inhibition of in vitro angiogenesis by lymphotoxin and interferon-γ
246. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
247. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis
248. Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies
249. Mammalian heparanase as mediator of tumor metastasis and angiogenesis
250. Inhibition of angiogenesis by interleukin 4
251. Inhibition of angiogenesis by thrombospondin-2
252. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production
253. Computer modelling of the receptor-binding domains of VEGF and PlGF
254. Different signal transduction properties of KDR and Flt 1, two receptors for vascular endothelial growth factor
255. Alterations of mature arterioles associated with chronically reduced blood flow
256. Eph family transmembrane ligands can mediate repulsive guidance of trunk neural crest migration and motor axon outgrowth
257. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4
258. Tissue distribution and developmental expression of the messenger RNA encoding angiogenin
259. Vascular-specific growth factors and blood vessel formation
260. Vasculogenesis, angiogenesis, and growth factors: Ephrins enter the fray at the border
261. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane
262. Embryonic mesodermal defects in alpha 5 integrin-deficient mice
263. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer
264. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis
265. Role of prostaglandin E 1 and copper in angiogenesis